For clinics, med spas and telehealth. And everyone in peptides and longevity.

Friday, Nov. 13, 2026

FDA adds eye-risk warning to every approved GLP-1 label

Also in this issue: Hims revenue up 49%, ad spend up 6.5%

Forwarded this? Get it weekday mornings.

Take. Branded GLP-1s now carry an eye-risk warning on the label. Compounded vials have no FDA-approved label. Those patients hear the warning only if the clinic says it. We'd put it in the consent forms this week at any clinic that sells compounded semaglutide or tirzepatide on "same active ingredient" copy. Patients will ask why their clinic never mentioned it if they hear it on the news first.

FDA said Monday it is requiring makers of every approved GLP-1 drug to add non-arteritic anterior ischemic optic neuropathy, or NAION, to the Warnings and Precautions section of their labels. NAION cuts blood flow to the front of the optic nerve. It can cause sudden, painless vision loss in one eye, sometimes permanent. The list runs from Ozempic, Wegovy and Rybelsus to Mounjaro, Zepbound and Lilly's oral Foundayo.

The risk FDA found is small. Across 126 randomized trials, it counted 6.4 NAION cases per 100,000 person-years on GLP-1 drugs against 3.8 on comparators. That was 15 probable cases in all. FDA's own Sentinel study of type 2 diabetes patients found no higher risk against SGLT-2 drugs. It did find a higher risk against DPP-4 drugs.

FDA tells prescribers to have patients report sudden vision loss in one eye right away. Suspected cases go to an ophthalmologist. FDA says to consider stopping the drug if NAION occurs.

BMO analysts, quoted by BioSpace, see "limited risk to our obesity coverage." They called it a Warnings and Precautions update "rather than a restriction on approved indications." FDA's notice names approved products only. It says nothing about compounded semaglutide or tirzepatide.

Tools and Tech

Cerbo extends its AI scribe to telehealth visits

Cerbo, an EHR used by cash-pay functional, longevity and concierge practices, says its built-in AI Scribe now drafts chart notes from Cerbo Telemedicine and Zoom visits. The provider has to sign off on each note before it saves. Existing AI Scribe users get the telehealth version at no extra cost, per Cerbo's PR Newswire release.

A scribe included in the EHR makes a separate scribe subscription hard to justify. At renewal, we would cancel a standalone scribe if Cerbo's covers the same visits.

The Signal

Telehealth

Hims & Hers revenue rises 49% as ad spend lags

Hims & Hers reported $890 million in third-quarter revenue, up 49% from a year earlier, in its earnings release Monday. U.S. revenue rose 21%. Revenue outside the U.S. more than quadrupled to $233 million. Gross margin fell to 57% from 74%. Marketing spend rose only 6.5%, to $247 million. CFO Yemi Okupe said the company was "intentionally pacing marketing spend ahead of several planned expansions to our platform in the fourth quarter." The release repeats Hims' early-2026 shift toward branded GLP-1s, with compounded versions on a limited scale. It doesn't break out weight-loss revenue. We'd expect Hims to spend harder on ads this quarter, on the same search terms clinics buy.

503A/503B

DataMEDS says its pharmacy sold a compounded peptide under HHS policy

DataMEDS AI, a Nasdaq-listed company, says its Corexa Pharmacy made its first commercial sale of one of the six peptides in HHS's enforcement-discretion policy: BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. The company release doesn't say which peptide, how much or at what price. Corexa is still working out pricing and will market to prescribing physicians. The policy covers 503A compounders only. HHS says it won't pursue them under stated conditions. It approves no drug. Clinics will get pharmacy pitches next. Ask each one for its state licenses and its bulk substance supplier, since the release itself flags reliance on third-party suppliers.

Medspa

Well Labs+ buys a Maryland medspa

Well Labs+, a 47-location medspa platform, bought surgeon-led Adoro Medical Spa in Severna Park, per the seller's advisor, Dresner Partners. Terms weren't disclosed.

In Court

Consumers sue a compounding pharmacy over GLP-1 marketing claims

Tameka Watson and Nicholas Forcier filed a proposed class action against Empower Clinic Services and its New Jersey unit, which does business as Empower Pharma, in federal court in New Jersey on Oct. 30, per the docket. Case tracker ClaimDepot says the complaint alleges Empower marketed its compounded semaglutide and tirzepatide as clinically proven, personalized and safely made. Those are allegations. No class is certified and Empower hasn't answered on the public docket. Clinic ads that repeat a pharmacy's claims face the same legal risk.

Wire

  • DEA's special-registration rule for telemedicine prescribing is still under White House review on reginfo.gov. The 90-day review mark is Monday, Nov. 23, with one 30-day extension allowed.
  • Comments on HHS's 503A peptide enforcement-discretion policy close Friday, Nov. 13, on Regulations.gov.
  • Zenoti now feeds booking and inventory data to Medvelle's AI purchasing service for medspas that opt in, per Zenoti.

Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.